This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Healthcare ETFs in Focus After Johnson & Johnson Q1 Earnings
by Zacks Equity Research
Johnson & Johnson reports Q1 results with both revenues and EPS beating estimates.
3 Dividend ETFs With High Inflows in April
by Zacks Equity Research
Consider these three dividend ETFs to fend off growing market uncertainty.
5 Drug Stocks Poised to Surpass on Earnings This Quarter
by Zacks Equity Research
The outlook for the upcoming first-quarter results looks bright.
Bristol-Myers (BMY) Down as Merck NSCLC Study Fares Better
by Zacks Equity Research
Bristol-Myers (BMY) stock declined as the company reported encouraging results from its NSCLC study but competitor Merck scored better in the same regard.
What's in Store for Novartis (NVS) This Earnings Season?
by Zacks Equity Research
We expect investors to focus on the performance of newly launched drugs when Novartis (NVS) reports its first-quarter results.
J&J (JNJ) Tops Q1 Earnings Estimates, Raises Sales Guidance
by Zacks Equity Research
J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2018. It maintains the previously issued earnings guidance for 2018 while increasing the sales range.
Shire Sells Oncology Unit Ahead of Takeda's Potential Offer
by Zacks Equity Research
Shire (SHPG) sells its oncology segment to France-based Servier for $2.4 billion. Takeda remains on track to make a potential offer for Shire.
Pharma Stock Roundup: NVS to Buy AveXis, PFE & ABBV's Drugs Succeed in Phase III
by Zacks Equity Research
Novartis (PFE) to buy AveXis for $8.7 billion. Merck's (MRK) Keytruda succeeds in another key lung cancer study. AbbVie's (ABBV) upadacitinib met endpoints in the 4th phase III study from its SELECT program.
Pfizer Starts Phase Ib for Duchenne Muscular Dystrophy Drug
by Zacks Equity Research
Pfizer (PFE) commences dosing in a phase Ib study, evaluating its gene therapy candidate, PF-06939926, for treating five to 12-yearold boys with duchenne muscular dystrophy.
Gene Therapy in Limelight on Novartis Deal: 3 Stocks in Focus
by Zacks Equity Research
With the announcement of Novartis (NVS) acquiring AveXis, a clinical stage gene therapy company, several companies have started to develop the therapy with many of them having promising candidates in their pipelines.
Glaxo to Sell Rare Disease Gene Therapies to Private Biotech
by Zacks Equity Research
Glaxo (GSK) will divest its rare disease gene therapy drugs to private biotech Orchard Therapeutics in exchange for a 19.9% stake in the company as well as a seat on its board.
Top ETF Picks for Your IRA
by Neena Mishra
Low-cost, diversified ETFs are excellent investment vehicles to build retirement wealth.
Pfizer's Kidney Cancer Drug Misses Endpoint in Phase III
by Zacks Equity Research
Pfizer's (PFE) kidney cancer drug Inlyta (axitinib) fails to demonstrate a clear improvement in the primary endpoint of extending disease-free survival (DFS) in a late-stage study.
AbbVie's RA Candidate Meets Primary Endpoints in Phase III
by Zacks Equity Research
AbbVie's (ABBV) rheumatoid arthritis candidate, upadacitinib, meets both primary and secondary endpoints in the fourth phase III SELECT study for the given indication.
Agios Pharmaceuticals Shares Rise on Buyout Speculation
by Zacks Equity Research
Agios (AGIO) share price shoots up on probable acquisition by other biggies in the biotech industry. This optimism follows the news of Novartis striking a deal to buy gene therapy company, AveXis.
vTv Therapeutics Crashes on Alzheimer's Drug Study Failure
by Zacks Equity Research
vTv Therapeutics (VTVT) shares suffered a major blow when the company's late stage study on lead candidate, azeliragon, for the treatment of Alzheimer's failed.
Clovis' (CLVS) Rubraca Gets FDA Nod as Maintainence Therapy
by Zacks Equity Research
Clovis Oncology (CLVS) announces the FDA has granted label expansion of Rubraca to include maintenance treatment of ovarian cancer patients in second line setting, irrespective of BRCA mutation status. Shares up.
Biogen Cracks the Case With AbbVie for Humira Biosimilar
by Zacks Equity Research
Biogen (BIIB) and partner Samsung Bioepis resolve an ongoing patent row with AbbVie regarding Biogen's biosimilar version of AbbVie's arthritis drug, Humira, in the EU.
Pharma Stock Roundup: LLY's Cyramza Shines in Cancer Study, PFE & AZN in Focus
by Zacks Equity Research
Pfizer (PFE) inks new CAR-T deal, AstraZeneca (AZN) provides positive regulatory updates and Lilly's (LLY) Cyramza shows survival benefit in liver cancer study
Pfizer's Lung Cancer Candidate Gets FDA's Priority Review
by Zacks Equity Research
Pfizer's (PFE) regulatory application for dacomitinib gets accepted in the United States under priority review for non-small cell lung cancer. The EU also accepts the filing for the same indication.
Pfizer Inks New CAR-T Deal, In Talks With P&G for Unit Sale
by Zacks Equity Research
Pfizer (PFE) out-licenses CAR-T assets to Allogene Therapeutics to expedite development. CNBC report says Pfizer in talks with P&G regarding sale of its Consumer Healthcare unit.
The Zacks Analyst Blog Highlights: Facebook, UnitedHealth, Pfizer, McDonald's and MetLife
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Facebook, UnitedHealth, Pfizer, McDonald's and MetLife
The Zacks Analyst Blog Highlights: Pfizer, Unique Fabricating, Guess', Nordstrom and Ciner Resources
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Unique Fabricating, Guess', Nordstrom and Ciner Resources
Top Research Reports for Facebook, UnitedHealth & Pfizer
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), UnitedHealth (UNH) and Pfizer (PFE).
Alnylam Falls on Pfizer's Rare Disease Drug Success
by Zacks Equity Research
Shares of Alnylam (ALNY) fall by more than 8% after Pfizer reports top-line results from the phase III study of tafamidis.